Holen Sie sich die Stockscreener-App
8.05
2.16%
0.17
Vorhandelsmarkt:
8.25
0.20
+2.48%
Schlusskurs vom Vortag:
$7.88
Offen:
$7.93
24-Stunden-Volumen:
278.96K
Relative Volume:
0.69
Marktkapitalisierung:
$149.15M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-84.53M
KGV:
-1.3845
EPS:
-5.8145
Netto-Cashflow:
$-73.65M
1W Leistung:
+4.55%
1M Leistung:
-27.02%
6M Leistung:
-1.23%
1J Leistung:
-2.78%
1-Tages-Spanne:
$7.93
$8.46
1-Wochen-Bereich:
$7.53
$8.57
52-Wochen-Spanne:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.05 | 154.15M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Stock (US21833E1038): Nasdaq price action in focus on a quiet news day - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan - Stock Titan
Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan - Stock Titan
Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade - Stock Titan
Corbus Pharmaceuticals teases cancer, obesity data as key clinical readouts near - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals targets HPV-linked head and neck cancer with CRB-701 study - MSN
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near - Yahoo Finance
Liquidity Mapping Around (CRBP) Price Events - Stock Traders Daily
Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP: Lead oncology and obesity assets advance with pivotal data and strong financial runway - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock By Investing.com - Investing.com India
CRBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock - Investing.com
Insider Purchase: Chief Business Officer of $CRBP Buys 9,000 Shares - Moomoo
Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Guggenheim Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Quick Look at Today's Ratings for Corbus Pharmaceuticals(CRBP.US), With a Forecast Between $40 to $54 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study - Yahoo Finance
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today & Analysis - Gotrade
CRBP Q1 2026 Earnings: Narrower Loss Misses on Thin Volume; No Revenue YetWeak Earnings Momentum - thelegaladvocate.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Why (CRBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRBP Maintained by Wedbush -- Price Target Lowered to $30 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP) - Seeking Alpha
LifeSci Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study - Moomoo
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com South Africa
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Altmeyer Anne | Director |
Jun 10 '26 |
Sale |
7.91 |
2,412 |
19,088 |
7,579 |
| Jenkins John Kenneth | Director |
Jun 10 '26 |
Sale |
7.91 |
4,800 |
37,986 |
3,833 |
| Saxena Nishant C | Chief Business Officer |
Jun 03 '26 |
Buy |
7.58 |
9,000 |
68,220 |
75,300 |
| Saxena Nishant C | Chief Business Officer |
Jun 02 '26 |
Buy |
7.33 |
4,500 |
32,998 |
66,300 |
| Smethurst Dominic | Chief Medical Officer |
Mar 02 '26 |
Sale |
8.30 |
6,097 |
50,601 |
89,790 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):